Form 4: Esperion Therapeutics Executive Eric Warren Sells Shares to Cover Tax Obligations

Chief Commercial Officer of Esperion Therapeutics, Eric Warren, sold 108 shares of common stock on April 17, 2025, to satisfy tax obligations related to vested restricted stock units.

Summary

• On April 17, 2025, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, Inc. (ESPR), sold 108 shares of common stock.
• The sale was executed at a price of $0.978 per share.
• Following the transaction, Warren directly owns 370,218 shares of Esperion Therapeutics.
• The sale was conducted to cover tax obligations arising from the vesting of restricted stock units.
• Warren has granted a Limited Power of Attorney to Sheldon L. Koenig and Richard B. Bartram to execute SEC filings on his behalf.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an executive's stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax planning. The sale itself is small and unlikely to have a significant impact on the stock price.

Key Dates

Keywords

Esperion Therapeutics, Eric Warren, share sale, Form 4, SEC filing, Chief Commercial Officer, tax obligations, restricted stock units, beneficial ownership, power of attorney